{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.1","spread":"25.1","upperLimit":"83.1","value":"55.6"},{"groupId":"OG001","lowerLimit":"9.8","spread":"9.8","upperLimit":"65.5","value":"33.3"},{"groupId":"OG002","lowerLimit":"25.1","spread":"25.1","upperLimit":"83.1","value":"55.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"CBR was defined as the percentage of participants with BOR of CR, PR, or durable stable disease (SD) based on RECIST 1.1 (durable SD was defined as SD with duration of greater than \\[\\>\\] 11 weeks). CR was defined as disappearance of all target and non-target lesions. All pathological (whether target or non-target) must have a reduction in their short axis \\<10 mm. PR was defined as at least 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants with RMS received eribulin mesilate 1.4 mg/m\\^2, intravenous infusion on Days 1 and 8 and irinotecan hydrochloride 40 mg/m\\^2, intravenous infusion on Days 1 to 5 in every 21 days treatment cycle until disease progression, development of intolerable toxicity or withdrawal of consent.","id":"OG000","title":"Phase 2: RMS Cohort, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 40 mg/m^2"},{"description":"Participants with NRSTS received eribulin mesilate 1.4 mg/m\\^2, intravenous infusion on Days 1 and 8 and irinotecan hydrochloride 40 mg/m\\^2, intravenous infusion on Days 1 to 5 in every 21 days treatment cycle until disease progression, development of unacceptable toxicity or withdrawal of consent.","id":"OG001","title":"Phase 2: NRSTS Cohort, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 40 mg/m^2"},{"description":"Participants with EWS received eribulin mesilate 1.4 mg/m\\^2, intravenous infusion on Days 1 and 8 and Irinotecan hydrochloride 40 mg/m\\^2, intravenous infusion on Days 1 to 5 in every 21 days treatment cycle until disease progression, development of unacceptable toxicity or withdrawal of consent.","id":"OG002","title":"Phase 2: EWS Cohort, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 40 mg/m^2"}],"paramType":"NUMBER","populationDescription":"Full analysis set included all participants who received at least 1 dose of either study drug.","reportingStatus":"POSTED","timeFrame":"From the date of first dose to the date of first documentation of PD, or date of death, whichever occurred first up to approximately 2 years 4 months","title":"Phase 2: Clinical Benefit Rate (CBR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}